| 证券代码 | AAAP.O |
| 证券名称 | Advanced Accelerator Applications SA ADR |
| 证券类型 | 美国存托凭证 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2015-11-11 |
| 首发价格(元) | 16 USD |
| 首发数量(股) | 4688000 |
| 首发募资额(元) | 75,008,000.00 USD |
| 首发主承销商 | Jefferies LLC,Citigroup Global Markets Inc |
| 货币单位 | EUR |
| 公司名称 | Advanced Accelerator Applications S.A. |
| 注册地址 | 20 rue Rudolf Diesel, Saint Genis Pouilly, France |
| 办公地址 | 20 rue Rudolf Diesel, Saint Genis Pouilly, France |
| 成立日期 | 2002-03-04 |
| 董事会主席 | Claudio Costamagna |
| 公司属地 | France 法国 |
| 公司网址 | www.adacap.com |
| 电话 | +33 (4) 5099-3070 |
| 传真 | +33 (4) 5099-3071 |
| 公司简介 | Advanced Accelerator Applications S.A. (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products. AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology. AAA’s lead investigational therapeutic candidate, lutetium Lu 177 dotatate (Lutathera) is a Lutetium-177, or Lu-177, labeled somatostatin analogue peptide in development for the treatment of neuroendocrine tumors, or NETs, a significant unmet medical need. A New Drug Application and Marketing Authorization Application for lutetium Lu 177 dotatate are currently under review with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Lutetium Lu 177 dotatate has received orphan drug designation from both the FDA and EMA. AAA currently has 21 production and research & development facilities that manufacture both diagnostic and therapeutic Molecular Nuclear Medicine products, and over 520 employees in 13 countries (Belgium, Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, UK and US). |